This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Coady, M. A. Articles by Sellke, F. W. Search for Related Content PubMed Articles by Coady, M. A. Articles by Sellke, F. W. Related Collections CV surgery: aortic and vascular disease Other Vascular biology Related Article

(Circulation. 2009;119:2423-2425.)
© 2009 American Heart Association, Inc.

Editorial

Metallothionein Link to Bicuspid Aortic Valve–Associated Ascending Aortic Dilatation

Michael A. Coady, MD, MPH; Frank W. Sellke, MD

From the Division of Cardiothoracic Surgery, Alpert School of Medicine at Brown University, Providence, RI.

Correspondence to Michael A. Coady, MD, MPH, Division of Cardiothoracic Surgery, Alpert School of Medicine at Brown University, Rhode Island Hospital, 2 Dudley St, MOC 500, Providence, RI 02905.

Key Words: Editorials • aorta • metalloproteinases

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Bicuspid aortic valve (BAV) is the most common congenital heart defect, occurring in 1% to 2% of the general population.¹ Given the high incidence of sequelae, including aortic valve calcification and dysfunction, congenital aortic malformations, and aortic dilatation and dissection, it may account for considerable morbidity and mortality compared with other congenital cardiac abnormalities. The aortic dilatation that occurs with BAV occurs more frequently and at a younger age than it does in patients with trileaflet aortic valves, and the clinical significance of the correlation between BAV and ascending aortic dilatation is based on the potential for aortic dissection and rupture.² Defining a potential molecular biological basis for aneurysm formation in BAV is critical for understanding disease progression and designing strategies for intervention. Medical treatments that might mitigate or halt the progression of aneurysmal expansion may significantly decrease the incidence of rupture and death and reduce the number of patients requiring high-risk surgical interventions. Potential targets for medical therapy have only recently begun to be elucidated, and much remains unclear about the mechanism of aneurysm formation and expansion.

Article see p 2498

Unfortunately, the precise mechanisms underlying the development and progression of thoracic aortic disease in BAV patients have not been clearly delineated. Two logical considerations are most frequently believed to play a major role in this context: that the increased hemodynamic load placed on the proximal aorta may result in progressive aortic dilatation and that an as-yet unidentified genetic or developmental abnormality in the proximal aortic tissue clinically results . . . [Full Text of this Article]

Related Article:

Basal and Oxidative Stress–Induced Expression of Metallothionein Is Decreased in Ascending Aortic Aneurysms of Bicuspid Aortic Valve Patients

Julie A. Phillippi, Ekaterina A. Klyachko, John P. Kenny, IV, Michael A. Eskay, Robert C. Gorman, and Thomas G. Gleason
Circulation 2009 119: 2498-2506. [Abstract] [Full Text]